Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Palbo 125. Please consult your doctor.
CONSULT YOUR DOCTOR
Palbo 125 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Palbo 125 is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Palbo 125 may cause side effects which could affect your ability to drive.
It may cause fatigue in some people. If this happens, you should exercise caution when driving or using machines.
SAFE IF PRESCRIBED
Palbo 125 is safe to use in patients with kidney disease. No dose adjustment of Palbo 125 is recommended.
CAUTION
Palbo 125 should be used with caution in patients with liver disease. Dose adjustment of Palbo 125 may be needed. Please consult your doctor.
Medicine Overview of Palbo 125mg Capsule
Introduction
Palbo 125 is used to treat patients with certain types of breast cancer (estrogen receptor-positive, human epidermal growth factor receptor 2-negative) which have spread to other organs. It is given together with hormonal anticancer therapies. Palbo 125 should be taken with food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has...
... Show moreUses of Palbo 125
- Breast cancer
Side effects of Palbo 125
Common
- Fatigue
- Hair loss
- Rash
- Vomiting
- Diarrhea
- Nausea
- Decreased blood cells (red cells, white cells, and platelets)
- Infection
- Decreased appetite
- Fever
How to use Palbo 125
Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Palbo 125 is to be taken with food.
How Palbo 125 works
Palbo 125 is an anti-cancer medication. Cyclin dependent kinase 4 and 6 (chemical messengers) are downstream of signaling pathways which lead to the proliferation of cells. This medicine works by inhibiting cyclin dependent kinase 4 and 6, thus arrests the cancer cell cycle (cell growing process). It also targets the estrogen (hormone) receptor-positive breast cancer cells by disrupting the cell cycle.
Quick Tips
- Take it with food, preferably at the same time every day.
- If you forget to take the medicine or vomit, skip the missed dose and follow a regular schedule. Do not take a double dose to make up missed dose
- Use effective contraception method to prevent pregnancy while taking this medicine.
- It may cause dizziness. Avoid driving or any activity requiring mental focus until you know how it affects you.
- You may be asked for regular blood tests while taking this medication. Inform your doctor if you notice symptoms of infection like fever, chills, and weakness.
- Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.
- Do not stop taking the medication without talking to your doctor first.
Brief Description
Indication
Indicated for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer, in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women, or with fulvestrant in women with disease progression endocrine therapy
Administration
Hard Capsule: Should be taken with food. Take at the same time each day. Swallow whole, do not chew/crush/open. Avoid grapefruit products.
Adult Dose
Oral Hormone receptor positive, HER2-negative locally advanced carcinoma of breast, Hormone receptor positive, HER2-negative metastatic carcinoma of breast Adult: In combination with aromatase inhibitor, or in combination with fulvestrant in women who have received prior endocrine therapy: 125 mg once daily for 21 days, followed by 7 days off, repeat every 28 days until disease progression or unacceptable toxicity. Dosage Modifications Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline). Recommended dose reduction: 1st reduction: 100 mg once daily; 2nd reduction: 75 mg once daily; discontinue if dose reduction...
... Show moreRenal Dose
Renal impairment
Mild, moderate, or severe (CrCl >15 mL/min): No dose adjustment required
Hemodialysis: Not studied
Contraindication
Pregnancy and lactation.
Mode of Action
Palbociclib is a reversible, selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Cyclin D1, CDK 4 and 6 are downstream of multiple signalling pathways which lead to cellular proliferation. Inhibition of CDK4/6 reduces proliferation of breast cancer cell lines by blocking progression from G1 into S phase of the cell cycle.
Precaution
Neutropenia observed in clinical trials; febrile neutropenia also reported; monitor CBC count prior to starting drug and at the beginning of each cycle, as well as on Day 14 of the first 2 cycles, and as clinically indicated; dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop grade 3 or 4 neutropenia
Side Effect
>10% Neutropenia, all grades (75%) Neutropenia, grade 3 (48%) Leukopenia, all grades (43%) Fatigue, all grades (41%) Anemia, all grades (35%) Upper respiratory tract infection, all grades (31%) Stomatitis, all grades (25%) Nausea, all grades (25%) Alopecia, grade 1 (22%) Diarrhea, all grades (21%) Leukopenia, grade 3 (19%) Thrombocytopenia, all grades (17%) Decreased appetite, all grades (16%) Vomiting, all grades (15%) Peripheral neuropathy, all grades (13%) Asthenia, all grades (13%) Epistaxis, all grades (11%) 1-10% Neutropenia, grade 4 (6%) Anemia, grade 3 (5%) Diarrhea, grade 3 (4%) Thrombocytopenia, grade 3 (2%) Nausea, grade 3 (2%) Fatigue, grades 3/4 (2%) Asthenia,...
... Show moreInteraction
Increased plasma concentration and systemic exposure with strong CYP3A inhibitors (e.g. clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, indinavir, ritonavir, ritonavir-boosted lopinavir, nelfinavir, saquinavir, telaprevir, nefazodone, verapamil). Decreased plasma concentration with moderate CYP3A inducers (e.g. bosentan, efavirenz, etravirine, modafinil, nafcillin) or strong CYP3A inducers (e.g. carbamazepine, phenytoin, enzalutamide, rifampicin). May increase the plasma concentration of CYP3A substrates (e.g. ciclosporin, everolimus, sirolimus, tacrolimus, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine).
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
